CD274 and head and neck squamous cell carcinoma: To reduce toxicity as observed with classical chemotherapies and to enhance tumor-specificity, further research should determine whether combination of immune checkpoint inhibitors such as anti-PD-(L)1 antibodies with targeted agents improves HNSCC response rates and survival.